International Journal of Radiation Oncology * Biology * Physics
Volume 47, Issue 5 , Pages 1165-1167 , 15 July 2000

What is the Tpot for prostate cancer? Radiobiological implications of the equivalent outcome with 125I or 103Pd

  • Christopher R King, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Boston University School of Medicine, Boston, MAUSA
    • Massachusetts General Hospital, Boston, MAUSA
    • Corresponding Author InformationReprint requests to: Dr. Christopher R. King, Department of Radiation Oncology, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118

,Accepted 18 February 2000.

References 

  1. Cha CM, Potters L, Ashley R, et al.  Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;45:391–395
  2. Ling CC. Permanent implants using Au-198, Pd-103 and I-125 (Radiobiologic considerations based on the linear quadratic model). Int J Radiat Oncol Biol Phys. 1992;23:81–87
  3. Ling CC, Li WX, Anderson LL. The relative biologic effectiveness of I-125 and Pd-103. Int J Radiat Oncol Biol Phys. 1995;32:373–378
  4. Algan O, Stobbe CC, Helt AM, et al.  Radiation inactivation of human prostate cancer cells (The role of apoptosis). Radiat Res. 1996;146:267–275
  5. Leith JT, Quaranto L, Padfield G, et al.  Radiobiological studies of PC-3 and DU-145 human prostate cancer cells (X-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo). Int J Radiat Oncol Biol Phys. 1993;25:283–287
  6. DeWeese TL, Shipman JM, Dillehay LE, et al.  Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. J Urol. 1998;159:591–598
  7. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  8. Duschesne GM, Peters LJ. What is the α/β ratio for prostate cancer? rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;44:747–748
  9. King CR, Mayo CS. Is the α/β ratio of 1.5 from Brenner and Hall a modeling artifact?. Int J Radiat Oncol Biol Phys. 2000;47:536–538
  10. Haustermans KMG, Hofland I, Van Poppel H, et al.  Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:1067–1070
  11. Lee WR, Hanks GE, Corn BW, et al.  Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int J Radiat Oncol Biol Phys. 1995;31:21–24
  12. Schmid HP. Tumour markers in patients on deferred treatment (Prostate specific antigen doubling times). Cancer Surv. 1995;23:157–167
  13. Movsas B, Chapman JD, Horwitz EM, et al.  Hypoxic regions exist in human prostate carcinoma. Urology. 1999;53:11–18
  14. Rasey JS, Koh W-J, Evans ML, et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of fluoromisonidazole (A pretherapy study of 37 patients). Int J Radiat Oncol Biol Phys. 1996;36:417–428
  15. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58:515–528
  16. Dale RG. Radiobiological assessment of permanent implants using tumor repopulation factors in the linear-quadratic model. Br J Radiol. 1989;62:241–244
  17. Ling CC, Roy J, Sahoo N, et al.  Quantifying the effect of dose inhomogeneity in brachytherapy (Application to permanent prostatic implant with I-125 seeds). Int J Radiat Oncol Biol Phys. 1994;28:971–978
  18. King CR, DiPetrillo TA, Wazer DE. Optimal radiotherapy for prostate cancer (predictions for conventional external beam, IMRT and brachytherapy from radiobiologic models). Int J Radiat Oncol Biol Phys. 2000;46:165–172

PII: S0360-3016(00)00543-5

doi: 10.1016/S0360-3016(00)00543-5

International Journal of Radiation Oncology * Biology * Physics
Volume 47, Issue 5 , Pages 1165-1167 , 15 July 2000

Article Tools

* Image Usage & Resolution